grant
The Alzheimer's Disease Tau Platform Clinical Trial
Organization UNIVERSITY OF CALIFORNIA, SAN FRANCISCOLocation SAN FRANCISCO, UNITED STATESPosted 21 Sept 2023Deadline 31 Aug 2029
NIHUS FederalResearch GrantFY2024AD dementiaAD pathologyAccelerationAddressAlzheimer Type DementiaAlzheimer beta-ProteinAlzheimer disease dementiaAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's Amyloid beta-ProteinAlzheimer's DiseaseAlzheimer's amyloidAlzheimer's biomarkerAlzheimer's disease biological markerAlzheimer's disease pathologyAlzheimer's disease therapeuticAlzheimer's disease therapyAlzheimer's pathologyAlzheimer's therapeuticAlzheimer's therapyAlzheimers DementiaAlzheimer’s biological markerAlzheimer’s disease biomarkerAmentiaAmyloidAmyloid Alzheimer's Dementia Amyloid ProteinAmyloid Beta-PeptideAmyloid Protein A4Amyloid ProteinsAmyloid SubstanceAmyloid beta-ProteinAmyloid βAmyloid β-PeptideAmyloid β-ProteinAnatomic SitesAnatomic structuresAnatomyAutopsyAβBiologicalBiological MarkersBiologyBlindedBlood PlasmaBlood TestsBrainBrain Nervous SystemBrain scanCell Communication and SignalingCell SignalingChemotherapy ProtocolChemotherapy RegimenChemotherapy-Oncologic ProcedureClinicClinicalClinical TrialsClinical Trials DesignClinical assessmentsCombination Chemotherapy RegimenCombined Modality TherapyDataDecision MakingDegenerative Neurologic DisordersDementiaDepositDepositionDiseaseDisease ProgressionDisorderDrugsEncephalonEnrollmentFailureFutureGene AlterationGene MutationGenerationsGoalsHematologic TestsHematological TestsHematology TestingHereditaryIndividualInheritedInterventionIntervention StrategiesIntracellular Communication and SignalingLifeLightMR ImagingMR TomographyMRIMRIsMT-bound tauMagnetic Resonance ImagingMeasuresMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMedicationMultimodal TherapyMultimodal TreatmentNMR ImagingNMR TomographyNational Institutes of HealthNerve DegenerationNervous System Degenerative DiseasesNeural Degenerative DiseasesNeural degenerative DisordersNeurodegenerative DiseasesNeurodegenerative DisordersNeurologic Degenerative ConditionsNeuron DegenerationNew AgentsNuclear Magnetic Resonance ImagingOncologyOncology CancerOutcomePETPET ScanPET imagingPET positivityPETSCANPETTParticipantPathogenicityPatientsPharmaceutical PreparationsPharmacodynamicsPhasePhotoradiationPlacebo ControlPlacebosPlasmaPlasma SerumPositron Emission Tomography Medical ImagingPositron Emission Tomography ScanPositron-Emission TomographyPrimary Senile Degenerative DementiaQuimioterapiaRad.-PETRandomizedRegimenResearch ResourcesResourcesReticuloendothelial System, Serum, PlasmaSafetySamplingSeverity of illnessSham TreatmentSignal TransductionSignal Transduction SystemsSignalingSiteSumSymptomsSyndromeTemporal LobeTestingTherapeuticTherapeutic EffectTimeTracerUnited States National Institutes of HealthZeugmatographya beta peptideabetaabeta accumulationabeta aggregationabnormal tauabnormally aggregated tau proteinamyloid betaamyloid beta accumulationamyloid beta aggregationamyloid β accumulationamyloid β aggregationamyloid-b proteinanti-cancer researcharmaβ accumulationaβ aggregationbeta amyloid fibrilbio-markersbiologicbiologic markerbiological signal transductionbiomarkercancer chemotherapycancer researchclinical developmentclinical trial protocolcombination therapycombined modality treatmentcombined treatmentdegenerative diseases of motor and sensory neuronsdegenerative neurological diseasesdesigndesigningdisease severitydrug/agentefficacy studyefficacy trialenrollexperiencefilamentous tau inclusionimprovedinclusion criteriainterventional strategymicrotubule associated protein tau aggregationmicrotubule associated protein tau depositmicrotubule associated protein tau mutationmicrotubule bound taumicrotubule-associated protein tau mutationmicrotubule-bound taumulti-modal therapymulti-modal treatmentmutant taumutation in microtubule associated protein taumutation in microtubule-associated protein taunecropsyneural degenerationneurodegenerationneurodegenerativeneurodegenerative illnessneurofilamentneurological degenerationneuronal degenerationnew approachesnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovel approachesnovel strategiesnovel strategynovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachopen labelopen label studyp-taup-τpaired helical filament of taupathogenic taupathogenic tau gene mutationpathological change in tauphospho-tauphospho-τphosphorylated tauplacebo controlledplacebo grouppositron emission tomographic (PET) imagingpositron emission tomographic imagingpositron emission tomography positivitypositron emitting tomographypost-translational modification of taupostmortemposttranslational modification of taupre-clinicalpreclinicalprimary degenerative dementiaprodromal ADprodromal Alzheimer'sprodromal Alzheimer's diseaseprogramsrandomisationrandomizationrandomly assignedrecruitsafety testingsecondary analysissecondary end pointsecondary endpointself-aggregate tausenile dementia of the Alzheimer typesham groupsham therapysoluble amyloid precursor proteintargeted agenttautau PHFtau Proteinstau abnormalitytau accumulationtau aggregatetau aggregationtau factortau fibrillizationtau filamenttau intronic mutationtau mutationtau neurofibrillary tangletau oligomertau paired helical filamenttau pathological changetau phosphorylationtau polymerizationtau posttranslational modificationtau-1tau-tau interactiontemporal cortextherapeutic targettooltreatment effectuptakeτ Proteinsτ aggregationτ mutationτ phosphorylation
Description preview
PROJECT SUMMARY / ABSTRACT
Tau protein is an attractive AD therapeutic target because the amount and anatomical distribution of insoluble
tau at autopsy is strongly correlated with the symptoms and severity of disease during life. Multiple tau therapies
are now in clinical trials for AD, with many new agents entering the clinic. New approaches to…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click